Personalized Treatment by rTMS in Chronic Pain - Study2

This is a prospective, single-arm interventional study designed to evaluate the predictive value of a neurophysiological biomarker for repetitive transcranial magnetic stimulation (rTMS) response in chronic pain patients. The project aims to test if the effects of non-pharmacological, non-invasive pain treatment can be enhanced by employing brain connectivity information to guide the application of rTMS. Previous efficacy and safety trials have supported that current best practice for rTMS for pain relief in chronic pain patients, is applied to one cortical area: primary motor cortex (M1). However, only around 50% respond to the treatment. Since there is no current strategy to know which patient will respond to treatment, patients with chronic pain end up undergoing trial and error strategies, which delay their improvement. This is actually not different from challenges related to pharmacological treatment, where each medication only relieves pain in 30-40% of patients, and the choice of each medication is based on "trial-and-error basis".

Several strategies currently aim to provide a more individualized strategy for choosing analgesic interventions based on patient-related information. To allow for the design of efficacy trials in the future, the present project is based on a proof-of-concept, mechanistic design. It will employ M1 rTMS stimulation for pain reduction. However, based on everyone's brain signals as read by EEG recorded before the start of the treatment it will be determined whether the patient is most likely to respond or not. Therefore, before receiving a full rTMS treatment, patients will undergo a neurophysiological screening session using single-pulse TMS-EEG. Single-pulse TMS and EEG have been routinely used in the clinic as a part of the neurophysiological assessment of patients for decades but have not yet been used in the association as an attempt to try to guide who will become a responder to the treatment. In the screening session, single pulses TMS will be applied to the primary network hub used as current best-practice in therapeutic rTMS: M1. Concomitantly, the EEG oscillatory activity of this cortical area will be recorded, and the brain connectivity state will be assessed. By using information derived from a patient´s brain connectivity state using transcranial magnetic stimulation with electroencephalography (TMS-EEG), it will be determined if the participant is most likely to respond or not. High oscillatory activity is expected to result in becoming a non-responder.

A total of 90 subjects with chronic pain will be included in a double-blind, randomized two parallel-arm study aiming to be able to accurately predict who will become a responder and a non-responder based on high oscillatory activity.

In the initial baseline measurement, the subjects will fill out questionnaires and undergo neurophysiological assessments which include rest EEG, TMS-EEG of M1, rTMS-EEG, followed by a repetition of TMS-EEG of M1 and rest EEG. After this baseline measurement, the subjects will receive daily rTMS sessions targeting M1 (called induction phase) for 5 consecutive days (Monday to Friday). Each of the 5 daily stimulations will last 30 minutes, of which 15 minutes will be under treatment.

The induction phase will be followed by a 7-week maintenance phase, with 1 rTMS session per week (totalling 7 rTMS sessions). At the end of the maintenance phase, primary and secondary outcomes (questionnaires) will be collected to investigate the efficacy of the rTMS treatments. These questionnaires will also be sent to participants 12 weeks following end of treatment. A random subsample of 30 participants will be asked if they would like to participate in a second 3-hour neurophysiological assessment to investigate the changes in brain connectivity.

• Patients' Global Impression of Change [Time frame: Patients' Global Impression of Change will be investigated before the treatment, at the end of the course of treatment (8 weeks of treatment), and again after 3 months following the end of treatment.]
• Short Brief Pain Inventory [Time frame: Short Brief Pain Inventory changes will be investigated before the treatment, at the end of the course of treatment (8 weeks of treatment), and again after 3 months following the end of treatment.]
• Short McGill Pain Questionnaire [Time frame: Short McGill Pain Questionnaire changes will be investigated before the treatment, at the end of the course of treatment (8 weeks of treatment), and again after 3 months following the end of treatment.]
• Quality of sleep (VAS) [Time frame: Sleep VAS changes will be investigated before the treatment, at the end of the course of treatment (8 weeks of treatment), and again after 3 months following the end of treatment.]